6-K

UNITED STATES

 SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2020

Commission File Number: 001-36187

EVOGENE LTD.

  (Translation of Registrant’s Name into English)

13 Gad Feinstein Street

Park Rehovot P.O.B 2100

Rehovot 7612002 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

CONTENTS

Attached hereto and incorporated by reference herein are the following exhibits:

99.1 Press Release: Evogene Launches its New Branding to Reflect the Company's Expanded Vision and New Business Model.

99.2 Evogene Investor Presentation – May 2020.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: May 20, 2020 EVOGENE  LTD.
(Registrant)

By: /s/ Dorit Kreiner
——————————————
Dorit Kreiner
Chief Financial Officer

3

EXHIBIT INDEX

EXHIBIT NO.	DESCRIPTION
99.1	Press Release: Evogene Launches its New Branding to Reflect the Company's Expanded Vision and New Business Model.
99.2	Evogene Investor Presentation – May 2020.

4

EX-99.1

Exhibit 99.1

Evogene Launches its New Branding to Reflect the

Company's Expanded Vision and New Business Model

Rehovot, Israel – May 20, 2020 – Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN.TA), a leading computational biology company targeting to revolutionize life-science product development across several market segments, announces today its rebranding. The new corporate identity reflects the company’s expanded vision and new business model.

"Evogene has undergone a significant transformation in its offering over the past years, and we are actively working to portray our expanded vision and strategy to the business and investment community. I believe that this new branding represents our new offering and will serve us extremely well in communicating this to the broader market," stated Ofer Haviv, President & CEO of Evogene.

Established as a spin-off from Compugen Ltd. in 2002, Evogene was initially focused on applying its capabilities in computational biology in agriculture, and more specifically on improving seed traits based on genomic modification. Changes in the agriculture market and in consumer tastes and demand necessitated that Evogene broaden its vision and focus on several new target markets and segments. The significant capital raised in its 2013 IPO allowed the Company to execute this strategy, enhancing its technology and expanding to new market segments.

In the years that followed, the Company’s management took a series of steps that paved the path for its evolution. Two key decisions underlay this development; the first was expanding Evogene’s technological capabilities in computational biology to include development of products based on microbes and small molecules, in addition to genomics, and the second was to expand Evogene’s focus beyond agriculture, to human health. These decisions led to the creation of Evogene’s amassed computational biology capabilities – the CPB (Computational Predictive Biology) platform, which aims to substantially increase the probability of success, while reducing time and cost, of life-science product development. In parallel, the Company established diverse internal divisions, each leading the development of specific market-driven products while using the CPB platform as their competitive advantage.

In 2018, Evogene announced the revision of its corporate structure to accommodate its new broadened activities. The Company began the execution of this plan by establishing new dedicated subsidiaries, based on the activities of its existing divisions, focusing on downstream product development. Four new subsidiaries were established in the areas of human health and agriculture, including (in order of establishment): Biomica, AgPlenus, Lavie Bio and Canonic, joining Evogene’s previous subsidiary, Casterra. In parallel, Evogene continued to focus on improvements to its CPB platform, serving as a technological hub to be used by the whole group through licensing agreements.

Mr. Haviv continued, "Today, Evogene provides tailor-made computational-biology solutions for the discovery and development of products based on microbes, small molecules and genetic elements for life-science based industries, including: human health, agriculture and industrial applications.

"I believe that we are better-positioned than ever before to capture the value of our unique technology in two distinct ways – through our existing collaborations and through our independent subsidiaries.  We have several upcoming key milestones across our subsidiaries, which we believe will generate substantial value. Details on these milestones are available in our newly branded presentation, filed today.

"We are now ready to continue to harness the power of our CPB platform through additional collaborations with strategic partners and to benefit as a shareholder from our subsidiaries as their value is unlocked and becomes apparent." - Mr. Haviv concluded.

About Evogene Ltd.:

Evogene (NASDAQ: EVGN, TASE: EVGN.TA) is a leading computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. Incorporating a deep understanding of biology and leveraging Big Data and Artificial Intelligence, Evogene established its unique technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

For more information, please visit www.evogene.com

Forward Looking Statements:

This press release contains “forward-looking statements” relating to future events. These statements may be identified by words such as “may”, “could”, “expects”, “intends”, “anticipates”, “plans”, “believes”, “scheduled”, “estimates” or words of similar meaning. For example, Evogene is using forward-looking statements in this press release when it discusses capturing the value of its technologies, entering into collaboration agreements and its upcoming milestones. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, the global spread of COVID-19, or the Coronavirus, the various restrictions deriving therefrom and those risk factors contained in Evogene’s reports filed with the applicable securities authorities. In addition, Evogene and its subsidiaries rely, and expect to continue to rely, on third parties to conduct certain activities, such as their field-trials and pre-clinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines (including as a result of the effect of the Coronavirus), Evogene and its subsidiaries may experience significant delays in the conduct of their activities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

Evogene Investor Contact:	US Investor Relations:
Rivka Neufeld Investor Relations and Public Relations Manager E: IR@evogene.com T: +972-8-931-1940	Joseph Green Edison Group E: jgreen@edisongroup.com T: +1 646-653-7030
	Laine Yonker Edison Group E: lyonker@edisongroup.com T: +1 646-653-7035

EX-99.2

Exhibit 99.2

 INVESTORpresentation  May 2020   

 Forward Looking Statement  This presentation contains "forward-looking statements" relating to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting Evogene Ltd. or its subsidiaries (collectively, “Evogene” or “we”), that are considered “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the “PSLRA”) and other securities laws. Such forward-looking statements may be identified by the use of such words as “believe,” “expect,” “anticipate,” “should,” “planned,” “estimated,” “intend” and “potential” or words of similar meaning. For example, Evogene is using forward-looking statements in this presentation when it discusses its near-term value drivers, including statements to the effect that it will reach commercialization, regulatory approval or enter into collaboration agreements; its milestones for each of 2020, 2021 and 2022; its belief that its diverse portfolio mitigates the risk associated with each individual opportunity within its portfolio and in its product pipeline; and its estimated cash usage for its year ending December 31, 2020.  For these statements, Evogene claims the protection of the safe harbor for forward-looking statements contained in the PSLRA and other securities laws. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, including, without limitation, the global spread of COVID-19, or the Coronavirus, the various restrictions deriving therefrom, the extent of Evogene continuing to maintain its holdings in its subsidiary companies, whether Evogene is able to comply with regulatory requirements, the degree of Evogene’s success at adapting to the continuous technological changes in its industries, and those factors and risks described in greater detail in Evogene’s Annual Report on Form 20-F and in other reports it files and furnishes with the U.S. Securities and Exchange Commission and the Israel Securities Authority from time to time. In addition, Evogene relies, and expects to continue to rely, on third parties to conduct certain activities, such as its field-trials and pre-clinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines (including as a result of the effect of the Coronavirus), Evogene may experience significant delays in the conduct of its activities. All written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the previous statements. Except for any obligations to disclose information as required by applicable securities laws, Evogene disclaims any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or any other entity, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene.The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Evogene.    2 

 Agenda  IntroductionFields of activityTechnologySummary  3  Annex I - Evogene’s Main SubsidiariesAnnex II - Financial Fundamentals 

 4  Introduction 

 Our Vision  5  DECODING BIOLOGY  Revolutionizing life-science product development utilizing cutting edge computational biology technologies. 

 Ag-chemicalsIndustry  Life-science product development challenges  High cost, long time-to-market and low probability of success  6  Pharmaceutical Industry  Discovery anddevelopment costsof a new cropprotection product  Time to developa new cropprotection product    1995  2000  2005-8  2010-15  Number of years between the firstsynthesis and first sale of product  8.3  9.1  9.8  11.3  CDER’S* annual noveldrug approvals:2010-2019  Worldwide totalpharmaceutical R&Dspend in 2010-2024  Source: Phillips McDougall, 2016  Source: Phillips McDougall, 2016  Source: U.S. Food and Drug Administration  Source: Evaluate Pharma May 2019  *Center for Drug Evaluation and Research 

 The opportunity  Utilize comprehensive and integrated computational biology to substantially increase the probability of success, while reducing the time and cost of life-science product development.  7  HUMAN HEALTH  Agriculture  industrial applications 

 When biology meetsdisruptive technologies;introducing–   platform  8  BIG DATA  BIOLOGY  AI  Incorporating deep scientific understandings together with big data and advanced artificial intelligence technologies (AI), seeking to successfully discover & develop novel life-science based products.    - Computational Predictive Biology  Developed over two decades at an investment of tens of millions of dollars and validated through collaborations with industrial leaders 

 The powerof the CPB platform  9   DiscoveryComputational selection of the most promising candidates to initiate the product development process.   DevelopmentComputational driven solution addressingoptimization development challenges for the selected candidates, supporting the way to successful commercialization.  BIOLOGY  BIG DATA  AI 

 Tailor-made solutions for product development   The CPB platform provides tailor-made solutions for discovery and development for life-science products based on the following three core components:MicrobesSmall molecules Genetic elements   10  MICROBES  GENETIC ELEMENTS  SMALL MOLECULES        MicroBoostAI    CHEMPASSAI    GENERATORAI 

 SubsidiariesEstablish independent entities focusing on a defined commercial field with an exclusive license to use Evogene’s unique solutions for product development. The subsidiary may develop and commercialize products independently or through strategic collaborations. Potential revenue for EvogeneLicensing and research paymentsConsolidated revenuesDividends (subject to profits generated by subsidiary)Sale of equity  11  Business Model  1  2  CollaborationsJoint development with leading companies for defined products utilizing Evogene’s unique solution. Later-stage development and commercialization of the product will likely be done by the partner.   Potential revenue for EvogeneLicensing and research paymentsMilestone paymentsRevenue sharing 

 12  Fields of activity 

 INDUSTRIAL APPLICATIONS  AGRICULTURE  HUMAN HEALTH            MICROBES          SMALL MOLECULES          GENETIC ELEMENTS    13      Potential fields of activity    MicroBoostAI    CHEMPASSAI    GENERATORAI 

 INDUSTRIAL APPLICATIONS  AGRICULTURE  HUMAN HEALTH        Ag-Biologicals  MicrobiomebasedTherapeutics  MICROBES      Ag-Chemicals    SMALL MOLECULES    Ag-solutionsfor castoroil production  Seed Traits  MedicalCannabis  GENETIC ELEMENTS    14      Current life-science based products under development    MicroBoostAI    CHEMPASSAI    GENERATORAI 

 INDUSTRIAL APPLICATIONS  AGRICULTURE  HUMAN HEALTH            MICROBES          SMALL MOLECULES          GENETIC ELEMENTS    Development & commercialization through subsidiaries and collaborations  15      Seed Traits [division]    MicroBoostAI    CHEMPASSAI    GENERATORAI 

 Subsidiaries - expected main near-term value drivers    2020    2021    2022    Extend pre-clinical study in immuno-oncology program  Initiate first GMP production of drug candidates in immuno-oncology program  Extend pre-clinical study in Inflammatory Bowel Disease (IBD) program  Proof of concept, first in man study, in the immuno-oncology program      Engagement with commercial partners for cultivation and production  Demonstrate yield improvementin cannabis lines under development  Pre-commercialactivity towardscommercialization in 2022  Demonstrate clinical effects of a developed line, based on dedicated research with a medical institution      Sign collaboration based on pre-Lead candidates from herbicide program  Reach a ‘Lead’ in herbicide program  Reach a POC for a herbicide tolerance gene trait, for a ‘Lead’ herbicide in development   Licensing agreementof ‘Lead’ herbicide candidate      Advance phase inbio-pesticide & bio-stimulant programs  File for regulatory approval for a wheat bio-stimulant product  Receive regulatory approval for a wheat bio-stimulant product   Advancement of a wheat bio-stimulant product to pre-commercial activities with early-adopter farmers    16  Collaboration  Regulation  Pipeline  Commercialization  *  * Additional milestone on slide 35  

 17  Technology 

               18    Efficacy  Safety  Selectivity  Shelf-life  Other  ProductLaunch  Candidate Selection    ProductDefinition              Discovery  Development  The challenge in creatinglife-science based products 

               19    Candidate Selection    ProductDefinition          Common practiceDiscovery – selection of product candidates mainly addressing efficacy   The challenge in creatinglife-science based products  Efficacy  Safety  Selectivity  Shelf-life  Other  ProductLaunch 

               20    Candidate Selection  ProductDefinition            Low probability of successLong time to marketHigh development costs      Development – inefficient optimization & difficulty in addressing a single challenge without impairing others  The challenge in creatinglife-science based products  Efficacy  Safety  Selectivity  Shelf-life  Other  ProductLaunch  Common practiceDiscovery – selection of product candidates mainly addressing efficacy  

 Evogene's solution:Discovery  21    Candidate Selection  ProductDefinition          A multi-attribute computational selection of product candidates, addressing relevant challenges using dedicated training data sets and AI.                  Efficacy  Safety  Selectivity  Shelf-life  Other  ProductLaunch 

 Evogene's solution:Development  22    Candidate Selection  ProductDefinition          A multi-attribute computational analysis, addressing a specific development challenge of the selected candidate, without impairing its ability to address other product attributes.                Efficacy  Safety  Selectivity  Shelf-life  Other  ProductLaunch 

 23  Evogene’s tailor-made solution   DevelopmentComputational driven solution for guiding and assessing the optimization process of the selected core component, without impairing other key product attributes.   DiscoveryComputational prediction of candidates, to serve as the product’s core-component, addressing multiple key product attributes.          MicroBoostAI    CHEMPASSAI    GENERATORAI 

 24  summary 

   Evogene group  25      *Evogene holdings in its applicable subsidiaries  IndustrialApplications  100%*  Castor Oil ProductionCastor seeds &growth protocol  HumanHealth  Microbiome basedTherapeuticsImmuno-oncologyGI- gastrointestinal- related disordersMDRO – multi-drug resistant organisms  Medical CannabisStable high yield of specific compoundsStable high yield oftotal compounds  90%*  100%*  Seed TraitsYield improvement and drought tolerancePlant diseaseInsect control  Agriculture  Ag ChemicalsHerbicidesInsecticidesFungicides  Ag BiologicalsBio-StimulantsBio-Pesticides  100%*  72%*  Internal division of Evogene  

 Investmenthighlights  26  Technological platform and diverse product portfolio to mitigate the risk associated with life-science investmentsEvogene offers the opportunity to invest in the technology of tomorrow, while its and its subsidiaries’ diverse and advanced product portfolios may mitigate the risk associated with an individual opportunity.  Value creation through subsidiary Example #1 In August 2019, Lavie Bio, secured a strategic investment from Corteva:$10 million dollars in cash,and transfer of Corteva Inc.’sholdings in its subsidiary,Taxon Biosciences.in exchange for ~ 28% ofLavie Bio’s shares.  Value creation through subsidiary Example #2 Wholly owned subsidiary, AgPlenus, recently entered into a strategic collaboration with Corteva for the development of a new MoA (Mode-of-Action) herbicide.   Significant milestones expectedBiomica - Proof of concept, first in man study, in the immuno-oncology program, expected in 2021.Canonic - Pre-commercial activity expected in 2021. Commercialization expected in 2022.AgPlenus – Reach ‘Lead’ chemical,the basis for a new MoA herbicide, expected in 2020.Lavie Bio – Advancement of a wheat bio-stimulant to pre-commercial activities with early-adopter farmers, expected in 2021. Commercialization expected in 2022. 

 THANK You! 

 Annex I:Evogene’s Main Subsidiaries  28 

 Human health  BIOMICA | CANONIC  29 

 Biomica's Mission  Discovery and development of novel therapies for microbiome-related human disorders using computational biology.  30  Product Pipeline  Immuno-oncology        BMC121      Combination therapy for cancerwith checkpoint inhibitors          BMC127      Combination therapy for cancerwith checkpoint inhibitors  GI related disorders      BMC321  |  Inflammatory Bowel Disorder (IBD)  BMC322  |  Inflammatory Bowel Disorder (IBD)  BMC426  |  Irritable Bowel Syndrome (IBS)  MDRO(Multi Drug resistant organisms)      BMC201  |  Clostridioides difficile infection (CDI)        | Human Microbiome 

 Immuno-Oncology Program – Preparation towards the anticipatedfirst in man proof of concept clinical trials(January 2020)  31    Biomica Enters New Agreement with Biose Industrie for Scale-up and GMP Production of Drug Candidates BMC121 & BMC127 for its Immuno-Oncology ProgramThe scale-up and GMP batch production is to support the preparation towards the anticipated first in man proof of concept clinical trialsRehovot, Israel – January 13, 2020Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN), announced today that it has entered a service agreement with Biose Industrie, a France based CDMO, for the scale-up production of its drug candidates, microbial consortia BMC121 & BMC127 for its Immuno-Oncology program. This agreement will accelerate the Company’s Immuno-Oncology program which is currently planned to enter the clinic in 2021 for proof of concept studies.Biose Industrie is a drug-GMP certified manufacturer of bacteria-based APIs and clinical and commercial products. Biomica engaged with Biose for the scale-up development and GMP production of a clinical batch of its drug candidates. 

 Milestones  Extend pre-clinical study in immuno-oncology program.Initiate first GMP production of drug candidates immuno-oncology program.  32  Proof of concept, first in man study, in the immuno-oncology program.Extend pre-clinical study in IBD program.  2020  2021 

 Canonic’s Mission  Commercialize precise & stable medical cannabis products for better therapeutic effects using computational biology.  33  Product Pipeline  Precise  Stable enhancement of specific active compoundsMedical indication focusCompound profile focus    | Medical Cannabis  MetaYield  Stable enhancement of total plant compoundsIncreased compounds per plantIncreased compounds per area   

 Initiation of Breeding and Cultivation of Cannabis Varieties with Unique Genomic Profiles(November 2019)  34    Canonic Announces Initiation of Cultivation and Breeding of Cannabis Varieties withUnique Genomic Profiles for the Development of Medical Cannabis ProductsThis announcement follows successfully importing a collection of widely genetically diverse cannabis lines, establishing specialized R&D facilities, and receiving regulatory approval from the Israeli Medical Cannabis Agency (IMCA)Rehovot, Israel – November 6, 2019Canonic, a wholly owned subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN) focused on the development of medical cannabis products, announces today the initiation of its cultivation and breeding program of cannabis varieties with unique genomic profiles for the development of medical cannabis products. The initiation of cannabis cultivation follows: (1) successfully importing widely genetically diverse cannabis lines originating from different territories, (2) establishment of cannabis dedicated R&D facilities, including greenhouses, a molecular lab and tissue culture rooms and (3) receipt of the required regulatory approvals from the Israeli Medical Cannabis Agency (IMCA). 

 Milestones  Demonstrate yield improvement incannabis lines under development.Engagement with commercial partners for cultivation and production.Conduct pre-clinical studies to support the development of Canonic’s medical cannabis products.  35  Pre-commercial activity with firstcannabis variety towards commercialization in 2022.Demonstrate clinical effects of Canonic varieties based on dedicated research with a medical institution.  2020  2021 

 Agriculture  AgPlenus | Lavie Bio  36 

 AgPlenus Mission  Design of next generation effective, sustainable and safer crop protection products by leveraging computational biology.  37  Product Pipeline  Herbicide  Novel MOA (Mode-of-Action)  Existing MOA optimization  | Ag-Chemicals  Insecticide  Novel SoA (Site-of-Action)  AI optimization  Fungicide  Existing MOA optimization       

 Strategic collaborationwith Corteva for the development of novel herbicides(March 2020)  38    Corteva Agriscience and AgPlenus Announce Collaboration for the Development of Novel HerbicidesCollaboration to address rise in global weed resistance using Corteva’s product discovery and development expertise and AgPlenus’ internal novel herbicide pipeline Wilmington, DE., USA and Rehovot, Israel – March 25, 2020 Corteva Agriscience (NYSE: CTVA), a leading pure-play agriculture company, and AgPlenus, a subsidiary of Evogene Ltd., (NASDAQ: EVGN, TASE: EVGN), today announced that they have entered into a multi-year collaboration for the development of novel herbicides. The collaboration will combine Corteva’s strengths in crop protection product discovery and development with AgPlenus’ expertise in designing effective and sustainable crop protection products using predictive biology.By leveraging their complementary expertise, Corteva and AgPlenus will address the rise of global weed resistance, created in-part by the absence of new modes of action (MoAs) for weed control over the past 30 years. Successful products resulting from the collaboration will enter a multi-billion-dollar market. 

 Milestones  39    Reach a POC for a herbicide tolerance gene trait, for a ‘Lead’ herbicide in development. Licensing agreement of ‘Lead’ herbicide candidate.  2020  2021  Sign collaboration based on pre-Lead candidates from herbicide program.Reach a ‘Lead’ in herbicide program. 

 Lavie Bio Mission  Improve food quality, sustainability and agricultural productivity through the introduction of microbiome based ag-biological products using computational biology.  40  Product Pipeline  Bio-Stimulants      Wheat      Corn      Bio-Pesticides      Mildew, fruit rots      Fusarium and seedlings disease      Bio-Insecticides          | Ag Biologicals 

 Corteva Investmentin Lavie Bio  Corteva’s investment included its holdingsin its wholly owned subsidiary TaxonBiosciences and $10 million to Lavie Bio.(August 2019)  41    Corteva Agriscience to Invest in Evogene’s Agriculture Biologicals Subsidiary, Lavie BioInvestment Includes Equity and Corteva’s Shares in Taxon Biosciences for Shares in Lavie BioWilmington, Del., USA and Rehovot, Israel – Aug. 7, 2019Corteva, Inc. (NYSE: CTVA), a leading pure-play agriculture company, and Evogene Ltd. (NASDAQ, TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced today that Corteva will make an investment in Evogene’s agriculture biologicals subsidiary, Lavie Bio (Lavie). The transaction includes the exchange of all shares of Corteva’s wholly owned subsidiary Taxon Biosciences along with an equity investment by Corteva in Lavie. As consideration for the Taxon Biosciences shares and equity investment, Corteva will be issued approximately 30 percent of Lavie’s equity while Evogene will hold approximately 70 percent of Lavie’s equity.Taxon Biosciences’ capabilities are expected to provide significant synergetic value to Lavie and accelerate the development of Lavie’s products. Taxon Biosciences’ assets, including a large microbial collection and product candidate pipeline, will be integrated into Lavie’s pipeline, accelerating Lavie’s ‘biology driven design’ approach and its product development. 

 Milestones  42    Receive regulatory approval for a wheat bio-stimulant product. Advancement of a wheat bio-stimulant to pre-commercial activities with early-adopter farmers.  2020  2021  Advance phase in bio-pesticide & bio-stimulant programs. File for regulatory approval for a wheat bio-stimulant product. 

 Annex II:Financial Fundamentals  43 

 Key Financials:Balance Sheet  Key Points:Consolidated cash position: ~$47 million as of 31.12.2019 No debtEstimated net cash usage for 2020 (without Lavie Bio):$14-$16 millionListed on TASE (2007) and NASDAQ (2013)  44  Thousands of US $  31.12.2019  31.12.2018  Current Assets  49,027  55,488  Long-Term Assets  22,337*  3,206  Total Assets  71,364  58,694  Current Liabilities  5,729  5,431  Long-Term Liabilities  5,418  2,957  Equity attributable to equity holders of the Company   50,144  50,053  Non-controlling interest   10,073  253  Total Liabilities & Shareholders Equity  71,364  58,694    *~$17 million attributed to intangible assets (net) following Corteva’s investment in Lavie Bio  44